Sun Pharma Rises After Settling Patent Litigation With Actavis

As part of the agreement, Ranbaxy along with its partners Cipher Pharm and Galephar Pharma, has entered into a non-exclusive license agreement with Actavis under the Dublin-headquartered company may start selling its generic version of Absorica in the US on 27 December 2020 (nine months before the expiration of the patents in September 2021) or earlier under certain circumstances, Sun Pharma said.

#Actavis #CipherPharm #GalepharPharma #Ranbaxy